Back to Journals » OncoTargets and Therapy » Volume 11

Genetic association between HER2 and ESR2 polymorphisms and ovarian cancer: a meta-analysis

Authors Tang L, Li J, Bao M, Xiang J, Chen Y, Wang Y

Received 18 August 2017

Accepted for publication 16 January 2018

Published 1 March 2018 Volume 2018:11 Pages 1055—1066


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Faris Farassati

Liang Tang,1,2 Jianming Li,1,3 Meihua Bao,1,2 Ju Xiang,1,2 Yiwei Chen,1,2 Yan Wang1,2,4

1Department of Human Anatomy, Histology and Embryology, Institute of Neuroscience, Changsha Medical University, Changsha, People’s Republic of China; 2Department of Human Anatomy, School of Basic Medical Science, Changsha Medical University, Changsha, People’s Republic of China; 3Department of Neurology, Xiang-ya Hospital, Central South University, Changsha, People’s Republic of China; 4Department of Human Anatomy, Experiment Center for Function, Changsha Medical University, Changsha, People’s Republic of China

Objective: The estrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER2) each play an important role in female cancers. This study aimed to investigate the genetic association between three common single nucleotide polymorphisms (SNPs) and the risk of ovarian cancer. The SNPs investigated in this study were ESR2 rs1271572 and rs3020450 and HER2 rs1801200.
Methods: In this study, databases were electronically searched in a meta-analysis. Databases used were PubMed, Embase, China National Knowledge Infrastructure (CNKI), Wanfang and Cochrane library. Case–control studies on the association between ESR2 and HER2 polymorphisms were selected according to inclusion and exclusion standard. Articles were evaluated for quality, and data were extracted.
Results: A total of 13 articles with 5,461 cases and 7,603 controls were included in this meta-analysis. The recessive model of ESR2 rs1271572 was shown to be significantly associated with the risk of ovarian cancer (p = 0.008, odds ratio [OR] [95% confidence interval {CI}] = 1.13 [1.03, 1.24]), and this significant association still existed in a subgroup analysis stratified by ethnicity (Asian: p = 0.04, OR [95% CI] = 1.92 [1.04, 3.56]; Caucasian: p = 0.02, OR [95% CI] = 1.12 [1.02, 1.23]). In addition, the distribution of the dominant model of ESR2 rs3020450 was significantly different in the total group (p = 0.02, OR [95% CI] = 0.71 [0.53, 0.95]) and the Caucasian subgroup (p = 0.02, OR [95% CI] = 0.67 [0.48, 0.94]). Furthermore, no significant association between allelic, dominant, codominant and recessive models of HER2 rs1801200 (V655I) and ovarian cancer was found (p > 0.05).
Conclusion: The recessive model of ESR2 rs1271572 and the dominant model of ESR2 rs3020450 might be susceptible factors for ovarian cancer.

Keywords: ESR2, ovarian cancer, HER2, meta-analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]